logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Partial Opioid Agonist class drugs

    FiltersReset Filters
    8 results

    • belbuca

      (buprenorphine hydrochloride)
      BioDelivery Sciences International Inc
      Usage: BELBUCA is indicated for managing severe and persistent pain requiring long-term opioid treatment when other options are inadequate. It is not intended for as-needed use and should be reserved for patients unable to tolerate or achieve relief with non-opioid or immediate-release opioids due to risks of addiction and overdose.

    • buprenorphine

      (BUPRENORPHINE)
      Rhodes Pharmaceuticals L.P.
      Usage: Buprenorphine Sublingual Tablets are indicated for treating opioid dependence, particularly during induction. They should be used as part of a comprehensive treatment plan that includes counseling and psychosocial support.

    • buprenorphine and naloxone

      (Buprenorphine and Naloxone)
      Rhodes Pharmaceuticals L.P.
      Usage: Buprenorphine and naloxone sublingual tablets are indicated for the maintenance treatment of opioid dependence, to be used alongside counseling and psychosocial support as part of a comprehensive treatment plan.

    • buprenorphine hydrochloride

      (Buprenorphine Hydrochloride)
      Hospira, Inc.
      Usage: Buprenorphine hydrochloride injection is indicated for managing severe pain requiring an opioid analgesic when alternative treatments are insufficient. It should be reserved for patients who cannot tolerate or achieve adequate pain relief from non-opioid analgesics or opioid combinations, and not used long-term without necessity.

    • buprenorphine hydrochloride and naloxone hydrochloride dihydrate

      (Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate)
      SpecGx LLC
      Usage: Buprenorphine and naloxone sublingual tablets are indicated for the maintenance treatment of opioid dependence, to be used alongside a comprehensive treatment plan that incorporates counseling and psychosocial support.

    • butrans

      (buprenorphine)
      Purdue Pharma LP
      Usage: BUTRANS is indicated for managing severe and persistent pain requiring long-term opioid treatment when other options are insufficient. It is not for as-needed use and is reserved for patients who cannot tolerate or have inadequate relief from alternative treatments due to the risks of addiction and overdose.

    • suboxone

      (buprenorphine hydrochloride, naloxone hydrochloride)
      INDIVIOR INC.
      Usage: SUBOXONE sublingual film is indicated for the treatment of opioid dependence and should be used as part of a comprehensive treatment plan that includes counseling and psychosocial support.

    • zubsolv

      (buprenorphine hydrochloride and naloxone hydrochloride)
      Orexo US, Inc.
      Usage: ZUBSOLV is indicated for the treatment of opioid dependence and should be used as part of a comprehensive treatment plan that includes counseling and psychosocial support.